{"schema_version":"secwatch.filing_event.v1","accession":"0001842952-23-000004","form_type":"8-K","ticker":"CNTX","cik":"0001842952","company_name":"Context Therapeutics Inc.","filed_at":"2023-01-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.068396+00:00","generated_at":"2026-06-20T20:28:24.564173+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Context Therapeutics highlights 2023 priorities: CTIM-76 candidate, ONA-XR data updates, cash runway into Q1 2024","bullets":["CTIM-76 nominated as Claudin 6 x CD3 bispecific antibody candidate; IND filing expected Q1 2024.","ONA-XR Phase 2 endometrial cancer (OATH) shows 77% 4-month PFS rate; additional data expected mid-2023.","ONA-XR Phase 2 breast cancer (SMILE) shows 44% 4-month PFS rate; additional data expected Q4 2023.","ELONA Phase 1b/2 breast cancer trial with Menarini's elacestrant opened and enrolled first patient.","Cash and equivalents $39.4M as of Sep 30, 2022; expected to fund operations into Q1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001842952-23-000004","json":"https://secwatch.observer/filing/0001842952-23-000004.json","markdown":"https://secwatch.observer/filing/0001842952-23-000004.md","text":"https://secwatch.observer/filing/0001842952-23-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1842952/000184295223000004/0001842952-23-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1842952/000184295223000004/cntx-20230104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T20:28:24.564173+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}